Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Background: In progressive multiple sclerosis (MS), glial activation is thought to be a relevant mechanism of disability progression. Therefore, in vivo assessment of the glial cell activity is, in the emerging treatment era of primary progressive MS (PPMS), more important than ever.Objectives: To t...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ahmed Abdelhak, Tilman Hottenrott, Estrella Morenas-Rodríguez, Marc Suárez-Calvet, Uwe K. Zettl, Christian Haass, Sven G. Meuth, Sebastian Rauer, Markus Otto, Hayrettin Tumani, André Huss
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2019-03-01
Col·lecció:	Frontiers in Neurology
Matèries:	SiMoA GFAP PPMS glial activation progressive multiple sclerosis neurofilaments
Accés en línia:	https://www.frontiersin.org/article/10.3389/fneur.2019.00280/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!